These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35172587)

  • 1. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
    Bourhis J; Burtness B; Licitra LF; Nutting C; Schoenfeld JD; Omar M; Bouisset F; Nauwelaerts H; Urfer Y; Zanna C; Cohen EE
    Future Oncol; 2022 May; 18(14):1669-1678. PubMed ID: 35172587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.
    Ferris RL; Mehanna H; Schoenfeld JD; Tahara M; Yom SS; Haddad R; König A; Witzler P; Bajars M; Tourneau CL
    Future Oncol; 2024 Apr; 20(12):739-748. PubMed ID: 38197296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
    Tao Y; Sun XS; Pointreau Y; Tourneau CL; Sire C; Gollmer K; Crompton P; Bourhis J
    Future Oncol; 2023 Aug; 19(26):1769-1776. PubMed ID: 37439181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
    Tao Y; Sun XS; Pointreau Y; Le Tourneau C; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Calderon B; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Damstrup L; Crompton P; Ennaji A; Gollmer K; Nauwelaerts H; Bourhis J
    Eur J Cancer; 2023 Apr; 183():24-37. PubMed ID: 36796234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Ferris RL; Harrington K; Schoenfeld JD; Tahara M; Esdar C; Salmio S; Schroeder A; Bourhis J
    Cancer Treat Rev; 2023 Feb; 113():102492. PubMed ID: 36640618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lee NY; Ferris RL; Psyrri A; Haddad RI; Tahara M; Bourhis J; Harrington K; Chang PM; Lin JC; Razaq MA; Teixeira MM; Lövey J; Chamois J; Rueda A; Hu C; Dunn LA; Dvorkin MV; De Beukelaer S; Pavlov D; Thurm H; Cohen E
    Lancet Oncol; 2021 Apr; 22(4):450-462. PubMed ID: 33794205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Vugmeyster Y; Ravula A; Rouits E; Diderichsen PM; Kleijn HJ; Koenig A; Wang X; Schroeder A; Goteti K; Venkatakrishnan K
    Clin Pharmacol Ther; 2024 Jan; 115(1):52-61. PubMed ID: 37777832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Le Tourneau C; Tao Y; Gomez-Roca C; Cristina V; Borcoman E; Deutsch E; Bahleda R; Calugaru V; Modesto A; Rouits E; Gollmer K; Vuagniaux G; Crompton P; Zanna C; Szyldergemajn S; Delord JP; Bourhis J
    Clin Cancer Res; 2020 Dec; 26(24):6429-6436. PubMed ID: 32994295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma.
    Powell SF; Mazurczak M; Dib EG; Bleeker JS; Geeraerts LH; Tinguely M; Lohr MM; McGraw SC; Jensen AW; Ellison CA; Black LJ; Puumala SE; Reed VJ; Miskimins WK; Lee JH; Spanos WC
    Invest New Drugs; 2022 Jun; 40(3):622-633. PubMed ID: 35312941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.
    Wong SJ; Torres-Saavedra PA; Saba NF; Shenouda G; Bumpous JM; Wallace RE; Chung CH; El-Naggar AK; Gwede CK; Burtness B; Tennant PA; Dunlap NE; Redman R; Stokes WA; Rudra S; Mell LK; Sacco AG; Spencer SA; Nabell L; Yao M; Cury FL; Mitchell DL; Jones CU; Firat S; Contessa JN; Galloway T; Currey A; Harris J; Curran WJ; Le QT
    JAMA Oncol; 2023 Nov; 9(11):1565-1573. PubMed ID: 37768670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
    Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
    Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
    Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
    Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
    Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
    Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.